Review Fees (Industry Sponsored Clinical Trials)
As a condition for NIH funding, all research subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) must be reviewed by the UNMC Institutional Biosafety Committee.
Examples of clinical trials subject to the NIH Guidelines (human gene transfer) include viral vector-based vaccines, mRNA vaccines, and gene-modified cell therapies such as CAR-T. Industry-sponsored clinical trials where a new IBC protocol is submitted on or after March 1st, 2026 will be subject to the following IBC review fees:
Fees for review of Industry Sponsored Clinical Trials:
Description |
Fee |
| Initial Review | $1500.00 per IBC protocol |
| Request for Change (Sponsor Initiated) | $750.00 |
| Annual Continuing Review | $750.00 |
| Study Closure | No Charge |
|
Effective Date: March 1, 2026
|
|
Please contact us at ibcora@unmc.edu if you have any questions.